Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 5/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2959529 | 0.93 | HTR3A (0.48) | HTR3ADPP4HTR2CSOS1CHRM1 | |
| SCHEMBL13217574 | 0.90 | HTR2C (0.53) | HTR3ADPP4HTR2CCHRM1NPC1 | |
| SCHEMBL13200880 | 0.89 | DPP4 (0.56) | HTR3ADPP4SOS1CHRM1PIM1 | |
| SCHEMBL13200864 | 0.87 | HTR3A (0.58) | HTR3ADPP4SOS1CHRM1PIM1 | |
| SCHEMBL8352589 | 0.87 | HTR3A (0.61) | HTR3ADPP4SOS1CHRM1PIM1 | |
| SCHEMBL13200743 | 0.86 | DPP4 (0.65) | DPP4HTR2CCHRM1 | |
| SCHEMBL13200873 | 0.86 | DPP4 (0.56) | HTR3ADPP4SOS1CHRM1PIM1 | |
| SCHEMBL2963767 | 0.84 | DPP4 (0.48) | HTR3ADPP4SOS1CHRM1PIM1 | |
| Trifluoroacetic Acid SCHEMBL2958554 | 0.83 | DPP4 (0.49) | HTR3ADPP4SOS1CHRM1PIM1 | |
| SCHEMBL13200858 | 0.81 | DPP4 (0.63) | HTR3ADPP4SOS1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | HTR3A 1879/4885DPP4 1/4885HTR2C 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.